Inhibitor of Apoptosis Proteins Limit RIP3 Kinase-Dependent Interleukin-1 Activation
James E Vince, W Wei-Lynn Wong, Ian Gentle, Kate E Lawlor, Ramanjaneyulu Allam, Lorraine O'Reilly, Kylie Mason, Olaf Gross, Stephen Ma, Greta Guarda, Holly Anderton, Rosa Castillo, Georg Haecker, John Silke, Juerg Tschopp
Immunity | CELL PRESS | Published : 2012
Awarded by NHMRC
Thanks to M. McKinlay and S.K. Chunduru for Smac mimetic compound (TetraLogic Pharmaceuticals) and D. Vaux, M. Leverkus, K. Schroder, and B. Croker for advice. We would also like to thank D. Huang (Walter and Eliza Hall Institute, Australia) for providing Bax and Bak knockout mice, V. Dixit (Genentech, USA) for Ripk3<SUP>-/-</SUP> mice, A. Strasser (Walter and Eliza Hall Institute, Australia) for Bid<SUP>-/-</SUP> mice, H. Korner (James Cook University, Australia) for Tnf<SUP>-/-</SUP> and Tnfrsfla<SUP>-/-</SUP> mice, B. Crocker (Waiter and Eliza Hall Institute, Australia) for the pEF IL-1-FLAG cDNA, and E. Latz (University of Massachusetts Medical School, USA) for the v-myc/v-raf immortalized macrophages. J.E.V. was supported by Human Frontiers and NHMRC C. J. Martin fellowships. G.H. is supported by a Deutsche Krebshilfe/Mildred Scheel-Stiftung grant and I.G. is supported by an EMBO Long Term Fellowship. J.S. is on the scientific advisory board at TetraLogic pharmaceuticals and is supported by NHMRC grants 541901, 541902, and 602516. L.O. is supported by NHMRC grant 1009145. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS.